According to the latest disclosure of the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA), the small molecular drug BPYT-01 aiming at treating Diabetes Mellitus, Type 2 has received implied permission for clinical trials. 

BPYT-01 is initially developed by Xishuangbanna Tropical Botanical Garden (XTBG, original research unit), Shanghai Institute of Materia Medica (original research unit), and Baiji Youtang (Guangdong) Pharmaceutical Technology Co., Ltd. (new drug development unit).  

Till now, the global highest research and development status of BPYT-01 is Phase 1 clinical. It is a small molecule drug. Its therapeutic areas are endocrinology and metabolic disease. Its active indication is diabetes melitus, type 2.  

Prof. Zhang Yumei is the principal investigator of the new drug in Xishuangbanna Tropical Botanical Garden (XTBG）.